McKesson Corporation (MCK - Free Report) is well-poised for growth, backed by strategic collaborations and strength in the distribution solutions segment. However, the company’s opioid-related litigation expenses pose a threat.
Shares of this Zacks Rank #2 (Buy) stock have gained 48.1% so far this year against the industry’s decline of 8.6%. The S&P 500 Index has fallen 12% in the same time frame.
The company — with a market capitalization of $53.3 billion — is a health care services and information technology company. Its earnings are anticipated to improve 9.9% over the next five years. The company beat earnings estimates in three of the trailing four quarters and missed once, the average surprise being 13%. The company’s earnings yield of 6.5% also compares favorable with the industry’s 4.1%.
What’s Favoring It?
McKesson continues to actively pursue deals, divestitures and acquisitions to drive growth. In April 2022, the company completed the divestiture of its retail and distribution businesses in the U.K. to Aurelius. During the fiscal fourth quarter of 2022, the company completed the sale of its Austrian business to Quadrifolia management and the sale of its remaining share of its German joint venture to Walgreens Boots Alliance. The company is currently progressing with the divesture of its European business. These divestitures will allow the company to focus on its key growth market — the United States.
In June, McKesson formed a joint venture with HCA Healthcare (HCA - Free Report) to create a fully integrated oncology research organization. Per the deal, McKesson and HCA Healthcare will integrate their respective research units — US Oncology Research (USOR) and Sarah Cannon Research Institute (SCRI). The newly created entity with the combined capabilities of SCRI and USOR is expected to boost clinical research, ramp up the development of drugs, lead to better data and analytics capabilities, and pave the way for a wider portfolio of clinical trials. The deal between McKesson and HCA Healthcare is likely to be completed later this year.
McKesson is a major player in the pharmaceutical and medical supplies distribution market. The Distribution Solutions segment caters to a wide range of customers and businesses and stands to benefit from increased generic utilization, inflation in generics, courtesy of several patent expirations in the next few years, and an aging population.
During the fiscal first quarter of 2023, McKesson’s growth was led by its strong performance across all segments, except the International segment, which was marred by unfavorable currency movement. The divestiture of McKesson’s Austrian business also hurt growth.
The company removed a major overhang during the fiscal first quarter by settling or signing a settlement agreement related to the opioid-related claims of all 50 states, as well as the District of Columbia and all eligible territories. These developments will close long-pending litigations, hurting the company’s goodwill, and will also reduce MCK’s legal expenses.
McKesson’s agreements with the U.S. government for COVID-19 vaccine distribution, kitting, and storage programs and COVID-19 tests are an added benefit.
What’s Hurting the Stock?
McKesson’s broad settlement of opioid-related claims of states and municipalities is likely to drive expenses for the company in the short term. The company recorded a pre-tax charge of $74 million during the fiscal first quarter of 2023 related to the settlement of an opioid-related claim with certain states and counties.
Estimates Trend
For fiscal 2023, the Zacks Consensus Estimate for revenues is pegged at $272.9 billion, indicating an improvement of 3.4% from the year-ago period’s reported figure. The same for adjusted earnings per share stands at $24.05, suggesting growth of 1.5% from the prior-year reported figure.
Stocks to Consider
A couple of other top-ranked stocks in the broader medical space are AMN Healthcare Services (AMN - Free Report) and Patterson Companies (PDCO - Free Report) .
AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 15.7%. The company currently sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare’s long-term earnings growth rate is estimated at 3.2%. AMN’s earnings yield of 10.7% compares favorably with the industry’s (2.4%).
Patterson Companies surpassed earnings estimates in each of the trailing four quarters, the average surprise being 16.5%. The company currently carries a Zacks Rank #2.
Patterson Companies’ long-term earnings growth rate is estimated at 7.9%. The company’s earnings yield of 7.7% compares favorably with the industry’s 4.1%.
Free Report Reveals How You Could Profit from the Growing Electric Vehicle Industry
Globally, electric car sales continue their remarkable growth even after breaking records in 2021. High gas prices have fueled his demand, but so has evolving EV comfort, features and technology. So, the fervor for EVs will be around long after gas prices normalize. Not only are manufacturers seeing record-high profits, but producers of EV-related technology are raking in the dough as well. Do you know how to cash in? If not, we have the perfect report for you – and it’s FREE! Today, don't miss your chance to download Zacks' top 5 stocks for the electric vehicle revolution at no cost and with no obligation.
>>Send me my free report on the top 5 EV stocks<<
McKesson Corporation (MCK - Free Report) is well-poised for growth, backed by strategic collaborations and strength in the distribution solutions segment. However, the company’s opioid-related litigation expenses pose a threat.
Shares of this Zacks Rank #2 (Buy) stock have gained 48.1% so far this year against the industry’s decline of 8.6%. The S&P 500 Index has fallen 12% in the same time frame.
The company — with a market capitalization of $53.3 billion — is a health care services and information technology company. Its earnings are anticipated to improve 9.9% over the next five years. The company beat earnings estimates in three of the trailing four quarters and missed once, the average surprise being 13%. The company’s earnings yield of 6.5% also compares favorable with the industry’s 4.1%.
What’s Favoring It?
McKesson continues to actively pursue deals, divestitures and acquisitions to drive growth. In April 2022, the company completed the divestiture of its retail and distribution businesses in the U.K. to Aurelius. During the fiscal fourth quarter of 2022, the company completed the sale of its Austrian business to Quadrifolia management and the sale of its remaining share of its German joint venture to Walgreens Boots Alliance. The company is currently progressing with the divesture of its European business. These divestitures will allow the company to focus on its key growth market — the United States.
In June, McKesson formed a joint venture with HCA Healthcare (HCA - Free Report) to create a fully integrated oncology research organization. Per the deal, McKesson and HCA Healthcare will integrate their respective research units — US Oncology Research (USOR) and Sarah Cannon Research Institute (SCRI). The newly created entity with the combined capabilities of SCRI and USOR is expected to boost clinical research, ramp up the development of drugs, lead to better data and analytics capabilities, and pave the way for a wider portfolio of clinical trials. The deal between McKesson and HCA Healthcare is likely to be completed later this year.
McKesson is a major player in the pharmaceutical and medical supplies distribution market. The Distribution Solutions segment caters to a wide range of customers and businesses and stands to benefit from increased generic utilization, inflation in generics, courtesy of several patent expirations in the next few years, and an aging population.
During the fiscal first quarter of 2023, McKesson’s growth was led by its strong performance across all segments, except the International segment, which was marred by unfavorable currency movement. The divestiture of McKesson’s Austrian business also hurt growth.
The company removed a major overhang during the fiscal first quarter by settling or signing a settlement agreement related to the opioid-related claims of all 50 states, as well as the District of Columbia and all eligible territories. These developments will close long-pending litigations, hurting the company’s goodwill, and will also reduce MCK’s legal expenses.
McKesson’s agreements with the U.S. government for COVID-19 vaccine distribution, kitting, and storage programs and COVID-19 tests are an added benefit.
What’s Hurting the Stock?
McKesson’s broad settlement of opioid-related claims of states and municipalities is likely to drive expenses for the company in the short term. The company recorded a pre-tax charge of $74 million during the fiscal first quarter of 2023 related to the settlement of an opioid-related claim with certain states and counties.
Estimates Trend
For fiscal 2023, the Zacks Consensus Estimate for revenues is pegged at $272.9 billion, indicating an improvement of 3.4% from the year-ago period’s reported figure. The same for adjusted earnings per share stands at $24.05, suggesting growth of 1.5% from the prior-year reported figure.
Stocks to Consider
A couple of other top-ranked stocks in the broader medical space are AMN Healthcare Services (AMN - Free Report) and Patterson Companies (PDCO - Free Report) .
AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 15.7%. The company currently sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare’s long-term earnings growth rate is estimated at 3.2%. AMN’s earnings yield of 10.7% compares favorably with the industry’s (2.4%).
Patterson Companies surpassed earnings estimates in each of the trailing four quarters, the average surprise being 16.5%. The company currently carries a Zacks Rank #2.
Patterson Companies’ long-term earnings growth rate is estimated at 7.9%. The company’s earnings yield of 7.7% compares favorably with the industry’s 4.1%.
Free Report Reveals How You Could Profit from the Growing Electric Vehicle Industry
Globally, electric car sales continue their remarkable growth even after breaking records in 2021. High gas prices have fueled his demand, but so has evolving EV comfort, features and technology. So, the fervor for EVs will be around long after gas prices normalize. Not only are manufacturers seeing record-high profits, but producers of EV-related technology are raking in the dough as well. Do you know how to cash in? If not, we have the perfect report for you – and it’s FREE! Today, don't miss your chance to download Zacks' top 5 stocks for the electric vehicle revolution at no cost and with no obligation.
>>Send me my free report on the top 5 EV stocks<<
Get the latest research report on MCK - FREE
Get the latest research report on PDCO - FREE
Get the latest research report on AMN - FREE
Get the latest research report on HCA - FREE